Creative medical technology holdings announces fda clearance of investigational new drug (ind) application for allostem™, a novel cell therapy for the treatment of type 1 diabetes

Allostem™ represents the first novel allogenic cellular therapy in the dorsal artery of the pancreas in the united states   phoenix , nov. 3, 2022 /prnewswire/ -- creative medical technology holdings, inc. (nasdaq: celz), an immuno-endocrine company working to revolutionize care through the development of potentially best-in-class regenerative therapeutics, today announced that the u.s. food and drug administration has cleared the company's investigational new drug (ind) application, enabling the company to proceed with initiating a clinical trial for type 1 diabetes using allostem™. allostem™ leverages a unique approach to harnessing the power of perinatal tissue derived cells® (prdc) to multi-potentialities, including self-renewal ability, low antigenicity, reduced toxicity, and large-scale clinical expansion.
CELZ Ratings Summary
CELZ Quant Ranking